Background: Neuroendocrine neoplasms (NENs) represent a heterogeneous group of tumors that pose significant therapeutic challenges due to their potential for progression, metastasis, and hormonal syndromes. Somatostatin analogs (SSAs) have emerged as a cornerstone in NEN treatment, offering both antisecretory and antiproliferative effects by targeting somatostatin receptors (SSTRs). Despite their proven efficacy, intrinsic and acquired resistance mechanisms, including receptor downregulation, tumor heterogeneity, and microenvironmental influences, limit their long-term effectiveness.
View Article and Find Full Text PDFIntroduction: Evidence on left ventricular (LV) mechanics, assessed by speckle tracking echocardiography (STE), in children and adolescents with elevated blood pressure (BP)/hypertension is scanty.
Aim: The aim of the present meta-analysis was to provide an updated information on LV systolic function phenotyped by global longitudinal strain (GLS) and LV ejection fraction (LVEF) in the setting of pediatric hypertension.
Methods: Following the PRISMA guidelines, systematic searches were conducted across bibliographic databases (Pub-Med, OVID, EMBASE and Cochrane Library) to identify eligible studies from inception up to November 30th 2024.
Background: Evidence on subclinical cardiac organ damage and, particularly on myocardial deformation, detected by speckle tracking echocardiography (STE), in patients with schizophrenia and bipolar disorder free from known cardiac disease is scanty. The aim of the present systematic review was investigate whether global longitudinal strain (GLS) could be a more sensitive index of systolic dysfunction than left ventricular ejection fraction (LVEF) in this setting, after having preliminary focused on LV structural and functional changes by standard echocardiography or magnetic resonance imaging (MRI).
Methods: To identify eligible studies targeting GLS in patients with schizophrenia and bipolar disorder systematic searches were conducted across bibliographic databases (Pub-Med, OVID, EMBASE and Cochrane library) following the PRISMA guidelines, from inception up to August 31, 2024.